Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
SMS Pharmaceuticals Ltd, RSD Finance Ltd, Grand Oak Canyons Distillery Ltd and Dishman Carbogen Amcis Ltd are among the other losers in the BSE's 'B' group today, 22 May 2026.
Suraj Ltd crashed 11.14% to Rs 231 at 14:11 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 202 shares were traded on the counter so far as against the average daily volumes of 164 shares in the past one month.
SMS Pharmaceuticals Ltd tumbled 10.61% to Rs 380.9. The stock was the second biggest loser in 'B' group.On the BSE, 48063 shares were traded on the counter so far as against the average daily volumes of 10072 shares in the past one month.
RSD Finance Ltd lost 10.20% to Rs 95.16. The stock was the third biggest loser in 'B' group.On the BSE, 2074 shares were traded on the counter so far as against the average daily volumes of 764 shares in the past one month.
Grand Oak Canyons Distillery Ltd slipped 8.06% to Rs 26.68. The stock was the fourth biggest loser in 'B' group.On the BSE, 1152 shares were traded on the counter so far as against the average daily volumes of 1780 shares in the past one month.
Dishman Carbogen Amcis Ltd fell 8.03% to Rs 195.8. The stock was the fifth biggest loser in 'B' group.On the BSE, 31448 shares were traded on the counter so far as against the average daily volumes of 51608 shares in the past one month.
For the full year,net profit rose 47.51% to Rs 101.99 crore in the year ended March 2026 as against Rs 69.14 crore during the previous year ended March 2025. Sales rose 13.30% to Rs 886.87 crore in the year ended March 2026 as against Rs 782.75 crore during the previous year ended March 2025.
Total operating expenses for the period under review aggregated to Rs 166.80 crore, up 19.0% YoY.
PBIDT improved by 34.1% to Rs 47.40 crore in Q3 FY26 from Rs 35.34 crore in Q3 FY25.
Profit before tax in Q3 FY26 stood at Rs 31.16 crore, up by 38.9% from Rs 22.44 crore recorded in Q3 FY25.
SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag.
Long term bank facilities (Rs 350.87 crore) - CARE A; Positive (reaffirmed, outlook revised from Stable)
Short term bank facilities (Rs 52.83 crore) - CARE A1 (upgraded from CARE A2+)
SMS Pharmaceuticals announced that the US Food and Drug Administration has approved its associate company VKT Pharma's reformulated Ranitidine tablets in 150mg and 300mg strengths. This approval marks the re-entry of this important acid-reducing medication into the US market after a five-year absence.
The approval by the US FDA comes after extensive safety testing and manufacturing improvements that address previous concerns regarding the formation of NDMA impurity. It is expected to increase patient access to this important medication for patients who rely on it for various health conditions.